2023

• Ghimire, K., Kale, A., Li, J., Julovi, S., O'Connell, P., Grey, S., Hawthorne, W., Gunton, J., Rogers, N. (2023). A metabolic role for CD47 in pancreatic β cell insulin secretion and islet transplant outcomes. Science Translational Medicine, 15(717). [More Information]
• Julovi, S., Dao, A., Trinh, K., O'Donohue, A., Shu, C., Smith, S., Shingde, M., Schindeler, A., Rogers, N., Little, C. (2023). Disease-modifying interactions between chronic kidney disease and osteoarthritis: A new comorbid mouse model. RMD Open, 9(3). [More Information]
• Cao, Q., Wang, R., Niu, Z., Chen, T., Azmi, F., Read, S., Chen, J., Lee, V., Zhou, C., Julovi, S., Zheng, G., George, J., Wang, Y., et al (2023). Type 2 innate lymphoid cells are protective against hepatic ischaemia/reperfusion injury. JHEP Reports, 5(10), 100837-100837. [More Information]

2022

• Trinh, K., Julovi, S., Rogers, N. (2022). The Role of Matrix Proteins in Cardiac Pathology. International Journal of Molecular Sciences, 23(3), 1338. [More Information]

2020

• Bulanadi, J., Xue, A., Gong, X., Bean, P., Julovi, S., De Campo, L., Smith, R., Moghaddam, M. (2020). Biomimetic Gemcitabine–Lipid Prodrug Nanoparticles for Pancreatic Cancer. ChemPlusChem, 85(6), 1283-1291. [More Information]
• Julovi, S., Sanganeria, B., Minhas, N., Ghimire, K., Nankivell, B., Rogers, N. (2020). Blocking thrombospondin-1 signaling via CD47 mitigates renal interstitial fibrosis. Laboratory Investigation, 100(9), 1184-1196. [More Information]
• Ghimire, K., Li, Y., Chiba, T., Julovi, S., Li, J., Ross, M., Straub, A., O'Connell, P., Rüegg, C., Pagano, P., Rogers, N., et al (2020). CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis. Cells, 9(7), 1-21. [More Information]
• Smith, R., Bulanadi, J., Gill, A., Rye, K., Hugh, T., Proschogo, N., Smith, S., Phillips, L., Gong, X., Julovi, S., Xue, A., et al (2020). Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice. Cancer Letters, 495, 112-122. [More Information]
• Hameed, A., Lu, D., Burns, H., Byrne, N., Chew, Y., Julovi, S., Ghimire, K., Zanjani, N., P’ng, C., Meijles, D., Yuen, L., Pleass, H., Rogers, N., Hawthorne, W., et al (2020). Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform. Scientific Reports, 10(1), 6930. [More Information]
• El-Rashid, M., Nguyen-Ngo, D., Minhas, N., Meijles, D., Li, J., Ghimire, K., Julovi, S., Rogers, N. (2020). Repurposing of metformin and colchicine reveals differential modulation of acute and chronic kidney injury. Scientific Reports, 10(1), 21968. [More Information]

2018

• Julovi, S., Martin, J., Baxter, R. (2018). Nuclear insulin-like growth factor binding protein-3 as a biomarker in triple-negative breast cancer xenograft tumors: Effect of targeted therapy and comparison with chemotherapy. Frontiers in Endocrinology, 9(MAR), 1-9. [More Information]
• Brown, K., Xue, A., Julovi, S., Gill, A., Pavlakis, N., Samra, J., Smith, R., Hugh, T. (2018). Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. Journal of Surgical Research, 227, 158-167. [More Information]

2017

• Martin, J., Julovi, S., Lin, Z., de Silva, H., Boyle, F., Baxter, R. (2017). Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Breast Cancer Research, 19(1), 1-14. [More Information]

2016

• Julovi, S., Xue, A., Thanh LE, T., Gill, A., Bulanadi, J., Patel, M., Waddington, L., Rye, K., Moghaddam, M., Smith, R. (2016). Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. PloS One, 11(3), 1-14. [More Information]

2015

• Xue, A., Julovi, S., Hugh, T., Samra, J., Wong, M., Gill, A., Toon, C., Smith, R. (2015). A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas. Pancreatology, 15(4), 397-404. [More Information]

2014

• Wong, M., Xue, A., Julovi, S., Pavlakis, N., Samra, J., Hugh, T., Gill, A., Peters, L., Baxter, R., Smith, R. (2014). Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20(10), 4047-4058. [More Information]

2013

• Julovi, S., Shen, K., McKelvey, K., Minhas, N., March, L., Jackson, C. (2013). Activated Protein C Inhibits Proliferation and Tumour Necrosis Factor alpha-stimulated Activation of p38, c-Jun NH2-Terminal Kinase (JNK) and Akt in Rheumatoid Synovial Fibroblasts. Molecular Medicine, 19, 324-331. [More Information]

2011

• Xue, M., Chow, S., Dervish, S., Chan, Y., Julovi, S., Jackson, C. (2011). Activated Protein C Enhances Human Keratinocyte Barrier Integrity via Sequential Activation of Epidermal Growth Factor Receptor and Tie2. Journal of Biological Chemistry, 286(8), 6742-6750. [More Information]
• Julovi, S., Ito, H., Nishitani, K., Jackson, C., Nakamura, T. (2011). Hyaluronan inhibits Matrix Metalloproteinase-13 in Human Arthritic Chondrocytes via CD44 and P38. Journal of Orthopaedic Research, 29(2), 258-264. [More Information]
• Julovi, S., Xue, M., Dervish, S., Sambrook, P., March, L., Jackson, C. (2011). Protease Activated Receptor-2 Mediates Activated Protein C-Induced Cutaneous Wound Healing via Inhibition of p38. American Journal of Pathology, 179(5), 2233-2242. [More Information]

2008

• Julovi, S., Ito, H., Hiramitsu, T., Yasuda, T., Nakamura, T. (2008). Hyaluronan inhibits IL-1β-stimulated collagenase production via down-regulation of phosphorylated p38 in SW-1353 human chondrosarcoma cells. Modern Rheumatology, 18(3), 263-270. [More Information]

2006

• Hiramitsu, T., Yasuda, T., Ito, H., Shimizu, M., Julovi, S., Kakinuma, T., Akiyoshi, M., Yoshida, M., Nakamura, T. (2006). Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-κB and p38. Rheumatology (Print Edition), 45(7), 824-832. [More Information]

2004

• Yasuda, T., Kakinuma, T., Julovi, S., Yoshida, M., Hiramitsu, T., Akiyoshi, M., Nakamura, T. (2004). COOH-terminal heparin-binding fibronectin fragment induces nitric oxide production in rheumatoid cartilage through CD44. Rheumatology (Print Edition), 43(9), 1116-1120. [More Information]
• Tadashi, Y., Mokoto, S., Julovi, S., Takashi, N. (2004). High molecular weight hyaluronan inhibits proinflammatory cytokine-induced production of matrix metalloproteinases by synovial cells and articular cartilage. Clinical Rheumatology and Related Research (Rinshou Ryuumachi), 16(3), 246-250.
• Julovi, S., Yasuda, T., Shimizu, M., Hiramitsu, T., Nakamura, T. (2004). Inhibition of Interleukin-1β-Stimulated Production of Matrix Metalloproteinases by Hyaluronan via CD44 in Human Articular Cartilage. Arthritis & Rheumatology, 50(2), 516-525. [More Information]
• Yasuda, T., Julovi, S., Hiramitsu, T., Yoshida, M., Nakamura, T. (2004). Requirement of mitogen-activated protein kinase for collagenase production by the fibronectin fragment in human articular chondrocytes in culture. Modern Rheumatology, 14(1), 54-60. [More Information]

2003

• Shimizu, M., Yasuda, T., Nakagawa, T., Yamashita, E., Julovi, S., Hiramitsu, T., Nakamura, T. (2003). Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. Journal of Rheumatology, 30(6), 1164-1172. [More Information]
• Yasuda, T., Poole, A., Shimizu, M., Nakagawa, T., Julovi, S., Tamamura, H., Fujii, N., Nakamura, T. (2003). Involvement of CD44 in Induction of Matrix Metalloproteinases by a COOH-Terminal Heparin-Binding Fragment of Fibronectin in Human Articular Cartilage in Culture. Arthritis & Rheumatology, 48(5), 1271-1280. [More Information]
• Yasuda, T., Shimizu, M., Nakagawa, T., Julovi, S., Nakamura, T. (2003). Matrix metalloproteinase production by COOH-terminal heparin-binding fibronectin fragment in rheumatoid synovial cells. Laboratory Investigation, 83(2), 153-162. [More Information]